GLI1 ELISA kit
- Known as:
- GLI1 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- DL-GLI1-Hu
- Product Quantity:
- 96T
- Category:
- Elisa Kits
- Supplier:
- WDSTD
- Gene target:
- GLI1 ELISA kit
Related genes to: GLI1 ELISA kit
- Gene:
- GLI1 NIH gene
- Name:
- GLI family zinc finger 1
- Previous symbol:
- GLI
- Synonyms:
- -
- Chromosome:
- 12q13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2016-01-15
Related products to: GLI1 ELISA kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: GLI1 ELISA kit
- -altered mesenchymal tumors represent a recently defined group of neoplasms molecularly characterized by gene fusions or amplifications. Although initially thought to share similar molecular alterations, including pericytoma with fusion, plexiform fibromyxoma, and gastroblastoma, these tumors are now recognized as distinct entities with specific clinicopathological features. Histologically, -altered mesenchymal tumors typically exhibit a multinodular growth pattern composed of relatively uniform epithelioid-to-ovoid cells arranged in nested formations. These nests are supported by a delicate arborizing capillary network and are often embedded in a myxoid stroma. Immunohistochemically, variable positivity for CD56, S100, CD10, smooth muscle actin, cyclin D1, and p16 has been reported. GLI1 immunohistochemistry is both highly sensitive and specific, serving as a valuable diagnostic marker in the appropriate context. Some -amplified tumors may show co-amplification of neighboring genes, including , and , which can result in variable immunoreactivity depending on amplicon size. These tumors can arise at a broad range of anatomical sites and occur across all age groups. Although -altered mesenchymal neoplasms were initially considered indolent, malignant cases with metastatic potential have been reported. Necrosis, high mitotic index, and large tumor size are associated with an increased risk of metastasis. Tumors with amplification generally demonstrate worse clinical outcomes than those driven by fusions. Definitive diagnosis requires molecular confirmation via next-generation sequencing and/or fluorescence in situ hybridization. Accurate recognition of -altered mesenchymal tumors has important diagnostic, prognostic, and therapeutic implications. Herein, we describe the clinicopathologic features of GLI1-altered neoplasms, including their molecular findings and the differential diagnosis with other tumors exhibiting overlapping morphology and immunoprofile. - Source: PubMed
Publication date: 2026/07/13
Rivas-Hernández RaquelGiner FranciscoPrados ElenaClaramunt ReyesLópez RaquelFernández AntonioMayordomo EmparLópez-Guerrero José AntonioNavarro SamuelLlombart-Bosch AntonioMachado Isidro - Peripheral nerve injury (PNI) is characterized by limited regenerative capacity and incomplete functional recovery. Schwann cells (SCs) are essential for nerve repair, but their clinical application is constrained by limited availability. Ectomesenchymal stem cells (EMSCs), derived from neural crest lineage, represent a promising alternative; however, their inefficient differentiation into SC-like cells remains a key limitation. This study investigated whether activation of Hedgehog signaling via Sonic hedgehog (Shh) could enhance SC-like differentiation and improve nerve regeneration. - Source: PubMed
Publication date: 2026/06/24
Zhang DengxinBian RuxiMa YaqiongYuan HuiqingWu XuechaoTang HongZhao Feifei - Fibrostenosis is a common and disabling complication of Crohn's disease (CD) with no reliable early biomarkers, limited treatment options and high postoperative recurrence. - Source: PubMed
Publication date: 2026/07/08
Wang DanshuZhao XiangyuYang QidiZhu DehaoLiao YijingZhao YizhouSun SishenWang JiaxinZhuang HaimingZhang ShuowenWang XinyuChe TianyiLi MingjiGu YubeiSun JingWu NingboYe YouqiongMao RenZhang YaoZou Duowu - Carpenter syndrome, caused by biallelic mutations in MEGF8 or RAB23, manifests with craniosynostosis through incompletely defined mechanisms. While both genes encode negative regulators of Hedgehog (Hh) signaling, we demonstrate that MEGF8 maintains cranial suture patency through a distinct, Hh-independent pathway. Loss of MEGF8 disrupts ubiquitination and lysosomal degradation of BMPR1A, leading to BMPR1A accumulation and hyperactivation of canonical BMP-SMAD1/5/9 signaling, which accelerates osteogenic differentiation of cranial mesenchyme. Using Megf8 mutant mice, we show tissue-specific specialization: limb defects are Hh-dependent and rescued by SMO inhibition, whereas craniosynostosis is BMP-driven and refractory to Hh blockade, with BMP type I receptor inhibition selectively rescuing the cranial phenotype. Comparative analyses reveal that MEGF8 and RAB23 promote osteogenic differentiation through distinct mechanisms-MEGF8 via ubiquitin-mediated BMPR1A turnover and BMP-SMAD activation, RAB23 through FGF-ERK signaling-despite both affecting GLI1-mediated transcription. Reintroduction of human MEGF8 in MEGF8-knockdown cells restores BMPR1A protein levels, validating the specificity of MEGF8-mediated BMPR1A regulation. These findings suggest that MEGF8 modulates BMP signaling post-transcriptionally, establishes tissue-specific regulatory mechanisms in syndromic disorders, and demonstrates how divergent pathways converge on shared phenotypes, with implications for pathway-specific therapeutic strategies. - Source: PubMed
Publication date: 2026/07/03
Hwangbo KoeunPark JihyunRho HyunjinWoo Dong-CheolSung Young HoonKim Soo-HyunSong JaewhanKo Hyuk Wan - The emphysematous phenotype is an important phenotype in chronic obstructive pulmonary disease (COPD), with substantial morbidity and mortality. The mechanisms underpinning the role of alveolar type II (AT2) cells in alveolar repair within this phenotype remain poorly understood. This study aimed to elucidate the role of PHLDA1, a potential stemness regulator in AT2 cells, on emphysema development. Utilizing mice model, we performed a targeted knockdown of PHLDA1 in AT2 cells and subsequently exposed these mice to tobacco smoke to assess the resultant severity of emphysema and related alveolar damage. We manipulated PHLDA1 expression in AT2 cells line or primary mouse AT2 cells to examine its influence on AT2 stemness-related processes- differentiation, proliferation, and wound closure ability. The specific pathway of PHLDA1 mediated in AT2 cells, as well as its interaction with the GLI1 protein, was further investigated. Mice with reduced PHLDA1 expression developed the emphysema independent of smoking exposure. PHLDA1 knockdown in AT2 cells attenuated their proliferation via the Hedgehog pathway, impairing wound closure ability in the emphysematous phenotype. We also discovered a binding relationship between PHLDA1 and GLI1, where PHLDA1 modulates the nuclear translocation of GLI1, thus regulating the Hedgehog pathway and influencing the stemness and proliferation of AT2 cells. Our study suggests that PHLDA1 is a critical factor in the proliferation process of AT2 cells via modulation of GLI1 nuclear translocation. This regulation is essential to the pathogenesis of the emphysematous phenotype in COPD, signifying potential therapeutic targets for intervention. - Source: PubMed
Publication date: 2026/07/04
Bai ShuangWang ShuaifuYe RuiWang DiMa MingxinZhao Li